tp-271
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2015 (NCT02724085)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- 30S ribosomal protein S12INHIBITOR
rpsL inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)[C@@H]5CCCN5C)cc(F)c4C[C@H]3C[C@@H]12- Mol. weight
- 558.56 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2057236 ↗
Also known as
- tp-271
- tp-271
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03450187 | Phase 1 | Mar 20, 2018 | National Institute of Allergy and Infectious Diseases (NIAID), Tetraphase Pharmaceuticals |
| NCT03234738 | Phase 1 | Aug 16, 2017 | National Institute of Allergy and Infectious Diseases (NIAID), Tetraphase Pharmaceuticals |
| NCT03024034 | Phase 1 | Feb 1, 2017 | National Institute of Allergy and Infectious Diseases (NIAID), Tetraphase Pharmaceuticals |
| NCT02724085 | Phase 1 | Dec 1, 2015 | National Institute of Allergy and Infectious Diseases (NIAID), Tetraphase Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 4 | 0 | 1 | 2015 |
| Tetraphase Pharmaceuticals | For profit | 4 | 4 | 1 | 2015 |
2 organizations
Page 1 / 1